Download PDF
Thromb Haemost 1967; 17(03/04): 418-422
DOI: 10.1055/s-0038-1654166
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

The Thrombolytic Effect of Heparin and a Heparin-Like Substance, SP 54

D. E. Fitz Gerald   *
1   Department of Medicine, University of Pittsburgh and the Department of Medicine, Montefiore Hospital, Pittsburgh
,
Isabel L. F. Szeto
1   Department of Medicine, University of Pittsburgh and the Department of Medicine, Montefiore Hospital, Pittsburgh
,
Joel Spero
1   Department of Medicine, University of Pittsburgh and the Department of Medicine, Montefiore Hospital, Pittsburgh
,
Jessica H. Lewis
› Author AffiliationsSupported by research grants from the National Heart Institute, United States Public Health Service (HE 02254 and HE 03036) and a grant from the Pennsylvania Heart Association, and the Western Pennsylvania Heart Association, and the Anathan Research Fund.
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The intravenous administration of heparin or SP 54 produced statistically significant reductions in the weights of experimentally induced jugular thrombi, which had been allowed to grow for 48, 72, or 120 hrs before treatment. The results observed in the smaller saphenous veins were less striking.

* Current address: Department of Medicine, Guy’s Hospital Medical School, London Bridge, S. E. London.


 

  • References

  • 1 Carey L. G, Williams R. D. Comparative effects of dicoumarol, tromexan and heparin on thrombus propagation. Ann. Surg 152: 919-922 1960;
    CrossrefPubMedGoogle Scholar
  • 2 Coons A. H, Kaplan M. H. Localization of antigen in tissue cells: II. Improvements in a method for the detection of antigen by means of fluorescent antibody. J. exp. Med 91: 1 1950;
    PubMedGoogle Scholar
  • 3 Fegan W. G, FitzGerald D. E. The treatment of venous insufficiency in pregnancy. J. Obstet. Gynaec. Cwlth 73: 122-125 1966;
    PubMedGoogle Scholar
  • 4 Goddan M. A, Edwards M. R, Tompkins V. N. Refinement of Fluorescent Antibody by Gel Filtration. Proc. Soc. exp. Biol. (N. Y.) 109: 96 1962;
    CrossrefPubMedGoogle Scholar
  • 5 Halse Th. Polyelectrolytes as activators of fibrinolysis and thrombolysis. Sangre (Barcelona) od. (Santiago) 9: 149-152 1964;
    PubMedGoogle Scholar
  • 6 Lewis J. H, Kerber C. W, Wilson J. H. Effects of fibrinolytic agents and heparin in intravascular clot lysis. Amer. J. Physiol 207: 1044-1048 1964;
    PubMedGoogle Scholar
  • 7 Lewis J. H, Szeto I. L. F, Bayer W. L, Takaori M, Safar P. Severe Hemodilution with Hydroxyethyl Starch and Dextrans. Arch. Surg 93: 941-950 1966;
    CrossrefPubMedGoogle Scholar
  • 8 Morris L. E, Balk Ph. The management and mismanagement of acute venous thrombosis of the extremities. Angiology 16: 339-345 1965;
    CrossrefPubMedGoogle Scholar
  • 9 Olesen E. S. A fibrinolytic system in human plasma activated by peptone or acid polysaccharides. Scand. J. clin. Lab. Invest 13: 410-415 1961;
    CrossrefPubMedGoogle Scholar
  • 10 Sandritter W. G, Schlüter G. Koppel Experimental thrombolysis in animal experiments with SP 54 and streptokinase. Med. Welt 1964; 2732-2739.
    PubMedGoogle Scholar
  • 11 Williams R. D, Karaffa F. Comparison of fibrinolysin and heparin on induced venous thrombosis and thrombolysis. Surg. Gynec. Obstet 121: 309-312 1965;
    PubMedGoogle Scholar
  • 12 Zweifler A. J. Standardized technique for the study of thrombus growth: effect of heparin therapy. J. Lab. clin. Med 60: 254-260 1962;
    PubMedGoogle Scholar